Skip to content
Visnia
CtrlK
EconomyAI buildoutMarket MapFundsWatchlist
Log in
Market cap
Revenue
Net income
Cash on hand
Gross margin
Net margin
EPS
P/E ratio
Search
Market mapFundsWatchlist
Visnia

ZZEVRA THERAPEUTICS, INC.

EconomyAI buildoutMarket MapFundsWatchlist
Log in
Z

ZEVRA THERAPEUTICS, INC.

  • Overview
  • Financial statements
  • Metrics
  • Quarterly earnings
  • Similar companies
  • News
  • Insider Transactions

News

News

  • Real-world use of arimoclomol in Niemann-Pick type C: Findings from a German Compassionate Use Programme
    Aug 25, 2026Zevra Therapeutics
  • Subgroup Analyses of US EAP Participants With Niemann-Pick Disease Type C Treated With Arimoclomol
    Aug 25, 2026Zevra Therapeutics
  • Long-term real-world safety and effectiveness of arimoclomol in individuals with NPC: Outcomes from the US early access program over a 4-year period
    Aug 5, 2026Zevra Therapeutics

    with NPC: Outcomes from the US early access program over a 4-year period

  • Arimoclomol in infants with Niemann-Pick disease type C: Results from the phase 2/3 open-label pediatric substudy
    Jun 22, 2026Zevra Therapeutics
  • Analysis of NPC1 Genotypes: Findings From the US Arimoclomol Expanded Access Program for Niemann-Pick Disease Type C
    Apr 10, 2026Zevra Therapeutics
  • Efficacy of Arimoclomol Combined With Miglustat at Months 3, 6, 9 and 12 of the Double-Blind, Randomized, Placebo-Controlled NPC002 Trial
    Feb 4, 2026Zevra Therapeutics
  • Multi-year subgroup analyses of Niemann-Pick disease type C participantstreated with arimoclomol in the US early access program (EAP)
    Feb 4, 2026Zevra Therapeutics
  • Real-world safety and effectiveness arimoclomol in patients with NPC:outcomes from the US early access program (EAP) over a 4-year period
    Feb 4, 2026Zevra Therapeutics
  • Long-term safety and effectiveness of arimoclomol adult and pediatricNiemann-Pick disease type C patients in the US early access program (EAP)
    Feb 4, 2026Zevra Therapeutics
  • Changing The Course of NPC: Long-term Evidence for Disease Modification in a Heterogenous Population
    Sep 23, 2025Zevra Therapeutics
  • Overview
  • Financial statements
  • Metrics
  • Quarterly earnings
  • Similar companies
  • News
  • Insider Transactions
$11.58Close ยท Sep 22, 2026